SCHEDULE: Leon Recanati Boosts Evogene Stake to 8.6%

Leon Recanati, a board member of Evogene Ltd., has increased his beneficial ownership to 8.6% by acquiring an additional 460,000 ordinary shares.

Summary

• Leon Recanati, a director of Evogene Ltd., has increased his beneficial ownership of the company's ordinary shares to 8.6%.
• This increase follows the purchase of an additional 460,000 ordinary shares on August 11, 2026, for $0.635 per share, totaling $292,100.
• The total beneficial ownership now stands at 1,354,836 ordinary shares, which includes 1,343,886 shares held directly and 10,950 shares underlying exercisable options.
• The reporting person has sole voting and dispositive power over all beneficially owned shares.
• The filing is an amendment to a previous Schedule 13D filing.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it indicates increased conviction from a board member, but does not signal a major strategic shift or immediate financial improvement.

Positives

• Increased beneficial ownership by a board member suggests confidence in the company's future prospects.
• The acquisition of 460,000 shares demonstrates a tangible investment by Leon Recanati.
• The reporting person holds sole voting and dispositive power, indicating direct control over these shares.

Negatives

• The filing does not disclose any new strategic plans or significant operational updates.
• The purchase price of $0.635 per share is relatively low, which could reflect the current market valuation of the stock.

Risks

• The filing does not explicitly mention any new risks beyond those previously disclosed in the original Schedule 13D.
• Potential for increased scrutiny from regulators or other investors due to the change in ownership percentage.

Future Outlook

The filing does not contain any new forward-looking statements or guidance. It primarily reports an increase in beneficial ownership.

Management Comments

• The reporting person does not currently have any plans or proposals that relate to or would result in any of the transactions or other matters specified in subparagraphs (a) through (j) of Item 4 of Schedule 13D, except as set forth herein or in the Original Statement.

Industry Context

StockSavvy.ai notes that agritech companies, like Evogene, are often subject to significant investor interest, and increases in beneficial ownership by insiders or significant shareholders can be interpreted as a signal of conviction, especially in a sector that can be capital-intensive and research-driven.

Comparison to Industry Standards

• No direct comparison to industry standards is provided within this filing.
• The filing focuses on individual shareholding changes rather than company-wide performance metrics that would be used for industry comparison.

Stakeholder Impact

• Shareholders: May view the increased stake by a board member as a positive signal of confidence, potentially influencing market sentiment.
• Management: The increased stake might align management's interests more closely with significant shareholders.
• Potential Investors: This filing could attract attention from investors looking for companies with insider conviction.

Next Steps

• The reporting person may continue to acquire or dispose of shares in the open market.
• Further amendments to Schedule 13D will be filed if there are material changes in beneficial ownership or intentions.

Key Dates

Keywords

Evogene Ltd., Schedule 13D, Beneficial Ownership, Leon Recanati, Shareholder, Investment, Director, Agritech